Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom.
暂无分享,去创建一个
[1] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.
[2] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[3] Helena Canhão,et al. FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries , 2014 .
[4] Désirée van der Heijde,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.
[5] Seoyoung C. Kim,et al. Changes in Use of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983–2009 , 2013, Arthritis care & research.
[6] N. Arden,et al. Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study , 2012, BMJ Open.
[7] T. Pincus,et al. Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis , 2012, Annals of Internal Medicine.
[8] M. Petticrew,et al. Using natural experiments to evaluate population health interventions: new Medical Research Council guidance , 2012, Journal of Epidemiology & Community Health.
[9] Jeffrey R Curtis,et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.
[10] C. Bombardier,et al. Quality care in seniors with new‐onset rheumatoid arthritis: A Canadian perspective , 2011, Arthritis care & research.
[11] G. Jürgens,et al. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. , 2010, Arthritis and rheumatism.
[12] D. Huscher,et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres , 2010, Annals of the rheumatic diseases.
[13] D. M. van der Heijde,et al. Extended Report , 2022 .
[14] John Wong,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.
[15] Zoe Stableford,et al. Guidelines British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis ( after the first 2 years ) , 2009 .
[16] L. Smeeth,et al. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? , 2008, Arthritis and rheumatism.
[17] D. Symmons,et al. Health state utility values: a description of their development and application for rheumatic diseases. , 2008, Arthritis and rheumatism.
[18] Jeffrey R Curtis,et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.
[19] J. Bridges,et al. Charting the possible impact of national guidelines on the management of rheumatoid arthritis , 2008, Scandinavian journal of rheumatology.
[20] A. Hingorani,et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. , 2007, Rheumatology.
[21] M. Liang,et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.
[22] N. Goodson,et al. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). , 2006, Rheumatology.
[23] Diane Lacaille,et al. Gaps in care for rheumatoid arthritis: a population study. , 2005, Arthritis and rheumatism.
[24] Craig R Ramsay,et al. INTERRUPTED TIME SERIES DESIGNS IN HEALTH TECHNOLOGY ASSESSMENT: LESSONS FROM TWO SYSTEMATIC REVIEWS OF BEHAVIOR CHANGE STRATEGIES , 2003, International Journal of Technology Assessment in Health Care.
[25] A. Gibofsky. American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.
[26] J. Wong,et al. Long-term morbidity, mortality, and economics of rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[27] G. Panayi,et al. Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.